CXCL8 and colorectal carcinoma: A randomized, double blind, placebo-controlled phase I clinical trial (IRCT2015110511288N9) also reported that the addition of oral fisetin (100 mg/day) to oxaliplatin/capecitabine treatment in stage II/III CRC patients significantly reduced the serum levels of C-reactive protein (hs-CRP), interleukin-8 (IL-8) and matrix metalloproteinase-7 (MMP-7) [267].